Immunic Historical Income Statement
| IMUX Stock | USD 1.11 0.02 1.77% |
Historical analysis of Immunic income statement accounts such as Other Operating Expenses of 54.8 M or Research Development of 87.4 M can show how well Immunic performed in making a profits. Evaluating Immunic income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immunic's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Immunic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunic is a good buy for the upcoming year.
Immunic |
About Immunic Income Statement Analysis
Immunic Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immunic shareholders. The income statement also shows Immunic investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Immunic Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Immunic. It is also known as Immunic overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Immunic's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.At this time, Immunic's Research Development is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 5.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 105.5 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 66K | 1.0M | 3.1M | 3.2M | Interest Income | 66K | 1.0M | 3.1M | 3.2M |
Immunic income statement Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 50K | 39K | 85K | 77K | 111K | 105.5K | |
| Interest Expense | 107K | 58K | 85K | 1.0M | 936.9K | 730.2K | |
| Other Operating Expenses | 37.0M | 49.0M | 91.7M | 86.5M | 99.2M | 54.8M | |
| Operating Income | (37.0M) | (49.0M) | (91.7M) | (119.5M) | (99.2M) | (94.3M) | |
| Ebit | (37.0M) | (49.0M) | (91.7M) | (120.4M) | (99.2M) | (94.3M) | |
| Research Development | 22.5M | 38.6M | 61.1M | 71.3M | 83.2M | 87.4M | |
| Ebitda | (37.0M) | (48.9M) | (91.6M) | (120.3M) | (99.1M) | (94.2M) | |
| Total Operating Expenses | 37.0M | 49.0M | 91.7M | 86.5M | 99.2M | 54.8M | |
| Income Before Tax | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (93.6M) | (88.9M) | |
| Total Other Income Expense Net | 2.1M | 5.0M | (1.3M) | (919K) | 5.6M | 5.9M | |
| Net Income | (34.8M) | (44.0M) | (92.8M) | (154.3M) | (93.6M) | (88.9M) | |
| Income Tax Expense | (107K) | (58K) | (151K) | 33.9M | 39.0M | 40.9M | |
| Selling General Administrative | 14.5M | 10.3M | 13.3M | 15.3M | 16.0M | 14.0M | |
| Net Income From Continuing Ops | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (93.6M) | (98.3M) | |
| Non Operating Income Net Other | 2.1M | 5.0M | (1.3M) | (919K) | (827.1K) | (785.7K) | |
| Net Income Applicable To Common Shares | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (108.4M) | (102.9M) | |
| Net Interest Income | 107K | 58K | 66K | 1.0M | 3.1M | 3.2M | |
| Reconciled Depreciation | 50K | 39K | 85K | 77K | 111K | 105.5K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.